Form 4: Celularity Inc. Director Diane L. Parks Reports Stock and Option Awards

Director Diane L. Parks reports the acquisition of restricted stock units and stock options in Celularity Inc.

Summary

• On December 19, 2024, Diane L. Parks, a director of Celularity Inc., was granted 67,416 restricted stock units (RSUs) and options to purchase 84,746 shares of Class A Common Stock.
• The RSUs and options were granted under the company's 2021 Equity Incentive Plan.
• The RSUs and options vest on the earlier of the one-year anniversary of the grant date (December 19, 2024) or the next annual stockholder meeting, contingent upon continuous service with Celularity Inc.
• Following the reported transaction, Parks beneficially owns 303,482 shares of Class A Common Stock and options to purchase 362,524 shares.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard disclosure of stock and option grants, which is neither particularly positive nor negative.

Positives

• The grant of RSUs and stock options aligns the director's interests with those of the shareholders.
• The vesting schedule incentivizes continued service with the company.

Future Outlook

The document does not contain specific forward-looking statements beyond the vesting schedule of the granted securities.

Industry Context

This filing is a routine disclosure of equity grants to a company director, a common practice in publicly traded companies to incentivize and retain key personnel. The size and terms of the grant would be benchmarked against similar companies in the biotechnology sector.

Comparison to Industry Standards

• Equity grants to directors are a standard practice in publicly traded companies, particularly in the biotech industry.
• The size of the grant and the vesting schedule are typical for director compensation packages, aligning with industry norms observed at companies like BioNTech or Moderna.
• The vesting period of one year is also a common feature, similar to equity grants at companies such as Amgen or Gilead Sciences.

Stakeholder Impact

• The grant of equity may have a slightly dilutive effect on existing shareholders.
• The equity grants incentivize the director to act in the best interests of the shareholders.

Key Dates